Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Fractyl Health, Inc. (NASDAQ:GUTS) has received a consensus recommendation of "Buy" from four covering brokerages, with an average 1-year price target of $6.90.
• The company's shares recently traded at $1.55, experiencing a decrease of 1.3%, while analysts estimate a yearly EPS of -1.61.
• Institutional investors have shown interest in Fractyl Health, with General Catalyst Group Management LLC acquiring a new position valued at approximately $7.9 million.

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have been assigned a consensus recommendation of "Buy" from the four brokerages that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $6.90.

A number of research firms recently issued reports on GUTS. LADENBURG THALM/SH SH began coverage on shares of Fractyl Health in a research report on Thursday, August 28th. They set a "buy" rating and a $3.60 target price on the stock. HC Wainwright dropped their target price on shares of Fractyl Health from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, September 26th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Fractyl Health in a research report on Saturday, September 27th. Finally, Canaccord Genuity Group dropped their target price on shares of Fractyl Health from $12.00 to $6.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors have recently added to or reduced their stakes in GUTS. General Catalyst Group Management LLC bought a new position in Fractyl Health during the second quarter valued at about $7,912,000. Woodline Partners LP lifted its stake in Fractyl Health by 47.2% in the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company's stock worth $615,000 after purchasing an additional 165,786 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Fractyl Health in the 2nd quarter worth approximately $181,000. Qube Research & Technologies Ltd purchased a new stake in Fractyl Health in the 2nd quarter worth approximately $129,000. Finally, Nuveen LLC purchased a new stake in Fractyl Health in the 1st quarter worth approximately $87,000.

Fractyl Health Trading Down 1.3%

Shares of NASDAQ GUTS traded down $0.02 during midday trading on Friday, reaching $1.55. The stock had a trading volume of 4,789,105 shares, compared to its average volume of 1,126,405. The firm has a market cap of $77.95 million, a price-to-earnings ratio of -0.75 and a beta of 2.27. Fractyl Health has a twelve month low of $0.83 and a twelve month high of $3.48. The company has a debt-to-equity ratio of 4.61, a quick ratio of 1.22 and a current ratio of 1.22. The company's 50 day moving average price is $1.18 and its 200 day moving average price is $1.44.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). As a group, sell-side analysts expect that Fractyl Health will post -1.61 EPS for the current year.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.